]>
IRCT20210609051526N1 IRCT 2021-06-14 Babol University of Medical Sciences Efficiency of linagliptin on insulin dosage in type 2 diabetes patients Efficiency of linagliptin on insulin dosage in type 2 diabetes patients with sever renal failure (randomized clinical trial) 2021-06-22 anticipated 96 Complete https://irct.ir/trial/56791 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be randomly assigned to two groups of 48 using 4 blocks and a ratio of 1: 1. The free website www.randomization.com will be used to generate the allocation sequence. The resulting sequence will be written on separate sheets and placed in sealed envelopes and will be provided to the lead researcher for study. 3 Type 2 diabetes. Intervention 1: Intervention group1: Treatment with a long-acting insulin regimen (based on the patient's body weight / weight and sugar) will be given subcutaneously. Intervention 2: Intervention group2:Treatment with long-acting insulin regimen (based on kg / body weight and patient sugar) will be used subcutaneously plus 5 mg of linaglyptin tablets (Abu Reihan Company) once a day. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is still no plan for its publish
public Neda Meftah
Ayatollah Rouhani Hospital, Daneshgah Square, Ganjafrooz Avenue
Babol Iran (Islamic Republic of) 47176-41367 +98 11 3233 8301 n.meftah@mubabol.ac.ir Babol University of Medical Sciences scientific Neda Meftah
Ayatollah Rouhani Hospital, Daneshgah Square, Ganjafrooz Avenue
Babol Iran (Islamic Republic of) 47176-41367 +98 11 3233 8301 n.meftah@mubabol.ac.ir Babol University of Medical Sciences Iran (Islamic Republic of) Type 2 diabetes Severe renal failure (GFR below 30) Age 80 - 18 years HbA1C between 7 and 10 18 years 80 years Both Inability to follow the patient Discontinue insulin or linagliptin E11 Type 2 diabetes mellitus Treatment - Drugs Treatment - Drugs Intervention group1: Treatment with a long-acting insulin regimen (based on the patient's body weight / weight and sugar) will be given subcutaneously. Intervention group2:Treatment with long-acting insulin regimen (based on kg / body weight and patient sugar) will be used subcutaneously plus 5 mg of linaglyptin tablets (Abu Reihan Company) once a day. Change insulin dose. Timepoint: At the beginning of the study and at the end of weeks 12 and 24. Method of measurement: Fasting blood sugar test, HBA1c test. Babol University of Medical Sciences Approved 2021-05-31 The Ethics Committee of Babol University of Medical Sciences Daneshgah Square, Ganjafrooz Avenue Babol Mazandaran Iran (Islamic Republic of)